United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$353.00 USD
+1.67 (0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $353.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 121 - 140 ( 611 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Broad Platform Progress-Our Thoughts on the IPF Opportunity
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3: Strong Beat Fueled by Growth Across the Board, Momentum Set to Continue
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
CHEST 2021: Poster Features New PK Data for Tyvaso DPI, Supports Bioequivalence
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso DPI CRL Pushes Approval to Mid-22 at the Latest; Outlook Unchanged
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Beat Builds Momentum Ahead of Potential Tyvaso DPI Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Amid Robust Treprostinil Initiatives, PAH Pipeline Asserts Momentum
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A